All In Biotech

Drug Trial Radar · NCT07903987

Assessment of the Value of FAPI and FDG-PET-CT in Diagnosis of Acute Phase Peyronie's Disease

The Use of FAPI-PET/CT and FDG-PET/CT Scan in Acute and Chronic Phase Peyronie's Disease for Detection of Active Fibroblasts and Inflammation in the Penis - a Pilot Study

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Dec 13, 2024

Primary completion

Aug 30, 2027

Study completion Sep 15, 2027

Sponsor

Lead sponsor
University Medical Center GroningenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
St. Antonius Hospital
First posted
Oct 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if FAPI-PET/CT and/or FDG-PET/CT scan is able to detect active fibroblast tissue and inflammation in patients with acute or chronic phase PD. * Does FAPI PET/CT scan or FDG PET/CT scan show any uptake of inflammatory tissue in patients with Peyronie's disease * Participants will undergo a FAPI PET/CT scan and FDG PET/CT scan after diagnosis of Peyronie's disease.

Conditions

  • Peyronie's Disease

Interventions

  • 68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor)Drug

    1 dosage for PET/scan of 200 MBq

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. In first ten PD patients detection of active fibroblasts (uptake of FAPI) and/or inflammation (uptake of FDG) in the penis with PET/CT scan. In second ten PD Patients no detection of chronic fibrotic tissue with FAPI and/or FDG uptake with PET/CT scan.Time frame: From enrollment to after the second PET/CT scan. The PET/CT Scan will be performed within 2 weeks after enrollment in the active phase. At least 24 hours between the two PET/CT scans. No timelimit in the chronic phase for first PET/CT scan.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • St Antoniusziekenhuis

    Nieuwegein, Utrecht, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.